RenovoRx is a clinical-stage biopharmaceutical company focused on developing therapies for the local treatment of solid tumors. It offers a therapy platform, RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) that combines the RenovoCath delivery system with small molecule chemotherapeutic agents that can be forced across the vessel wall using pressure, targeting anti-cancer drugs locally to the solid tumors. The company also develops RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath.